Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2005-004517-14-DE
EUCTR2005-004517-14-DEActive, not recruitingNot Applicable

Open study to determine the immunogenicity and reactogenicity of Influsplit SSW 2005/2006 in children from 6 years until 13 years of age - Flu-062

GlaxoSmithKline Biologicals0 sites240 target enrollmentStarted: October 5, 2005Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
240
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Healthy children or children with underlying disease aged from 6 to 13 years
  • •2. Only children, which were never vaccinated before or have never experienced a confirmed influenza before, can be enrolled
  • •3. Written informed consent obtained by the parents
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) no
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •4. Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceeding the vaccination, or planned use during the study period
  • •5. Acute disease at the time of enrolment
  • •6. History of allergic disease or reactions

Investigators

Similar Trials

Active, not recruiting
Not Applicable
Study to evaluate the immunogenicity, safety, and reactogenicity of TWINRIX ADULT containing 720 ELISA units of hepatitis A antigen and 20 µg of hepatitis B surface antigen, administered following a two-dose (0, 6 months) schedule in healthy children between the ages of 1 and 11 years.
EUCTR2015-001516-35-Outside-EU/EEAGlaxoSmithKline Biologicals178
Active, not recruiting
Not Applicable
Study to evaluate immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ Inactivated Polio Vaccine (Poliorix) in healthy Chinese toddlers.Booster immunisation of healthy children in the second year of life against poliomyelitis.
EUCTR2012-004513-14-Outside-EU/EEAGlaxoSmithKline Biologicals957
Active, not recruiting
Not Applicable
Immunogenicity and safety study of booster dose of GSK Biologicals’ IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) vaccine.Booster immunisation of healthy children in the second year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.
EUCTR2012-003324-20-Outside-EU/EEAGlaxoSmithKline Biologicals831
Active, not recruiting
Not Applicable
Immunogenicity and safety study of GSK Biologicals’ Infanrix-IPV+Hib™ vaccine.Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases.
EUCTR2011-005868-25-Outside-EU/EEAGlaxoSmithKline Biologicals985
Active, not recruiting
Not Applicable
Study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ inactivated polio vaccine (Poliorix) in infants.Primary immunisation of healthy infants in the first year of life against poliomyelitis
EUCTR2011-003167-30-Outside-EU/EEAGlaxoSmithKline Biologicals1,101